A Phase I Clinical Study of Gimatecan (ST 1481) in Patients With Platinum-resistant or Sensitive Relapsing/Refractory Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Latest Information Update: 06 Dec 2022
At a glance
- Drugs Gimatecan (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors Lee's Pharmaceutical
Most Recent Events
- 24 Jul 2019 New trial record